• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

血清游离轻链及重/轻链检测在监测IgG型骨髓瘤患者达到深度缓解后疾病活动中的临床应用

The clinical utility of serum free light chain and heavy/light chain assays in monitoring disease activity in patients with IgG myeloma after achieving a deep response.

作者信息

Shimizu Kazuyuki, Kamiya Yoshikazu, Itoh Junji, Okada Jun, Lim Merrell, Sugiyama Satoru

机构信息

Higashi Nagoya National Hospital Nagoya Japan.

Nagoya City Midori General Hospital Nagoya Japan.

出版信息

Clin Case Rep. 2017 Nov 28;6(1):96-102. doi: 10.1002/ccr3.1304. eCollection 2018 Jan.

DOI:10.1002/ccr3.1304
PMID:29375846
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5771931/
Abstract

Heavy/light chain (HLC) assay will enable us to evaluate the changes in the concentrations of iHLC and uHLC separately and to better identify whether the change observed is clonal or reactive. It would therefore aid in decision making for earlier implementation or discontinuation of treatment for patients with intact immunoglobulin multiple myeloma (MM).

摘要

重链/轻链（HLC）检测将使我们能够分别评估完整重链（iHLC）和不完整重链（uHLC）浓度的变化，并更好地确定观察到的变化是克隆性的还是反应性的。因此，它将有助于为完整免疫球蛋白多发性骨髓瘤（MM）患者的治疗方案是早期实施还是中止提供决策依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f83/5771931/8bf4433e5315/CCR3-6-96-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f83/5771931/5349188ad2cb/CCR3-6-96-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f83/5771931/38a33c1bba4b/CCR3-6-96-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f83/5771931/8bf4433e5315/CCR3-6-96-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f83/5771931/5349188ad2cb/CCR3-6-96-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f83/5771931/38a33c1bba4b/CCR3-6-96-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f83/5771931/8bf4433e5315/CCR3-6-96-g003.jpg

相似文献

1
The clinical utility of serum free light chain and heavy/light chain assays in monitoring disease activity in patients with IgG myeloma after achieving a deep response.血清游离轻链及重/轻链检测在监测IgG型骨髓瘤患者达到深度缓解后疾病活动中的临床应用
Clin Case Rep. 2017 Nov 28;6(1):96-102. doi: 10.1002/ccr3.1304. eCollection 2018 Jan.
2
Heavy/light chain assay in the monitoring of multiple myeloma.重链/轻链检测在多发性骨髓瘤监测中的应用。
Pathology. 2019 Aug;51(5):507-511. doi: 10.1016/j.pathol.2019.04.002. Epub 2019 Jun 25.
3
Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.不同免疫化学类型多发性骨髓瘤中免疫球蛋白重/轻链对（Hevylite）差异、选定实验室参数与分层系统之间的关系
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Mar;160(1):84-93. doi: 10.5507/bp.2015.032. Epub 2015 Aug 4.
4
Heavy/light chain assay as a biomarker for diagnosis and follow-up of multiple myeloma.重/轻链检测作为多发性骨髓瘤诊断和随访的生物标志物。
Clin Chim Acta. 2018 Apr;479:7-13. doi: 10.1016/j.cca.2018.01.010. Epub 2018 Jan 8.
5
[Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].[多发性骨髓瘤诊断时免疫球蛋白重链/轻链对（Hevylite）与血清蛋白凝胶电泳及散射比浊检测结果的关系分析]
Cas Lek Cesk. 2015;154(6):292-302.
6
Immunoglobulin heavy chain/light chain pairs (HLC, Hevylite™) assays for diagnosing and monitoring monoclonal gammopathies.免疫球蛋白重链/轻链配对（HLC，Hevylite™）检测在单克隆丙种球蛋白病的诊断和监测中的应用。
Adv Clin Exp Med. 2014 Jan-Feb;23(1):127-33. doi: 10.17219/acem/37036.
7
Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.异常重链/轻链比值和配对抑制增加了深度缓解多发性骨髓瘤患者的残留疾病检测灵敏度。
Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):293-296. doi: 10.1016/j.clml.2018.01.008. Epub 2018 Feb 19.
8
Laboratory and Clinical Settings of Heavy/Light Chain (HLC) Assays in the Management of Monoclonal Gammopathies and Multiple Myeloma.单克隆丙种球蛋白病和多发性骨髓瘤管理中重链/轻链（HLC）检测的实验室及临床背景
J Pers Med. 2023 Apr 27;13(5):743. doi: 10.3390/jpm13050743.
9
Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports.游离轻链与重链/轻链比值联合应用有助于单克隆丙种球蛋白病患者的诊断和监测：单机构经验及三例典型病例报告
Oncol Lett. 2016 Oct;12(4):2363-2370. doi: 10.3892/ol.2016.4965. Epub 2016 Aug 5.
10
Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression.IgM 型免疫球蛋白病中的免疫球蛋白缺乏作为预测疾病进展的有用生物标志物。
Clin Chem Lab Med. 2017 Aug 28;55(10):1598-1604. doi: 10.1515/cclm-2016-0748.

本文引用的文献

1
Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients.重链/轻链监测与多发性骨髓瘤患者的临床结局相关。
Leukemia. 2018 Feb;32(2):376-382. doi: 10.1038/leu.2017.209. Epub 2017 Jun 30.
2
Heavy/light chain ratio for the assessment of minimal residual disease in myeloma patients achieving complete response.用于评估达到完全缓解的骨髓瘤患者微小残留病的重链/轻链比值。
Br J Haematol. 2018 May;181(4):550-552. doi: 10.1111/bjh.14662. Epub 2017 Apr 25.
3
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
4
Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.未受累免疫球蛋白水平可预测多发性骨髓瘤患者的临床状态和无进展生存期。
Br J Haematol. 2016 Jul;174(1):81-7. doi: 10.1111/bjh.14026. Epub 2016 Mar 27.
5
Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy.血清游离轻链检测在未达到治疗完全缓解的多发性骨髓瘤患者中的应用价值
Leukemia. 2015 Oct;29(10):2033-8. doi: 10.1038/leu.2015.118. Epub 2015 May 12.
6
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.自体造血干细胞移植后实现严格完全缓解对多发性骨髓瘤的重要性。
J Clin Oncol. 2013 Dec 20;31(36):4529-35. doi: 10.1200/JCO.2013.49.0086. Epub 2013 Nov 18.
7
Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.免疫球蛋白重/轻链比值可提高浆细胞疾病的检出率和监测效果，识别残余疾病，并与多发性骨髓瘤患者的生存相关。
Leukemia. 2013 Jan;27(1):213-9. doi: 10.1038/leu.2012.197. Epub 2012 Jul 17.
8
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.受重链/轻链配对抑制所定义的未涉及免疫球蛋白的抑制是 MGUS 进展的一个危险因素。
Leukemia. 2013 Jan;27(1):208-12. doi: 10.1038/leu.2012.189. Epub 2012 Jul 11.
9
Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.免疫球蛋白 Ig'κ/Ig'λ 比值对多发性骨髓瘤患者预后的预测价值。
Leukemia. 2013 Jan;27(1):202-7. doi: 10.1038/leu.2012.159. Epub 2012 Jun 13.
10
Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation.自体造血干细胞移植后完全缓解的多发性骨髓瘤患者血清免疫球蛋白重/轻链比值的预后影响。
Biol Blood Marrow Transplant. 2012 Jul;18(7):1076-9. doi: 10.1016/j.bbmt.2012.03.004. Epub 2012 Mar 16.